No headlines found.
Acutus Medical Reports Second Quarter 2023 Financial Results
Globe Newswire (Mon, 7-Aug 4:01 PM ET)
Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Globe Newswire (Tue, 1-Aug 4:01 PM ET)
Acutus Medical to Present at the 43rd Annual Canaccord Growth Conference
Globe Newswire (Thu, 27-Jul 7:00 AM ET)
Acutus Medical to Announce Second Quarter 2023 Financial Results
Globe Newswire (Mon, 24-Jul 4:01 PM ET)
Acutus Medical Inc is an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated. The company designs, manufactures and markets a range of tools for catheter-based ablation procedures to treat various arrhythmias. Its product portfolio includes Novel access sheaths, Transseptal crossing tools, Diagnostic and mapping catheters, Ablation catheters, Mapping and imaging consoles and accessories, as well as Supporting algorithms and Software programs. It markets and sells its electrophysiology products worldwide to hospitals and electrophysiologists that treat patients with arrhythmias. It has a business presence in the United States and Europe.
Acutus Medical trades on the NASDAQ stock market under the symbol AFIB.
As of September 25, 2023, AFIB stock price declined to $0.59 with 120,406 million shares trading.
AFIB has a beta of -0.32, meaning it tends to be less sensitive to market movements. AFIB has a correlation of 0.00 to the broad based SPY ETF.
AFIB has a market cap of $17.28 million. This is considered a Sub-Micro Cap stock.
Last quarter Acutus Medical reported $5 million in Revenue and -$.60 earnings per share. This beat revenue expectation by $689,000 and exceeded earnings estimates by $.01.
In the last 3 years, AFIB stock traded as high as $34.35 and as low as $.40.
The top ETF exchange traded funds that AFIB belongs to (by Net Assets): VTI, VXF.
AFIB has underperformed the market in the last year with a return of -32.1%, while the SPY ETF gained +17.2%. In the last 3 month period, AFIB fell short of the market, returning -34.4%, while SPY returned -0.6%. However, in the most recent 2 weeks AFIB has outperformed the stock market by returning +26.8%, while SPY returned -2.6%.
AFIB support price is $.64 and resistance is $.76 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AFIB stock will trade within this expected range on the day.